Figure 3.

Mast cell serine proteases degrade IL‐17A. (A and B) WT and serglycin^−/− PCMCs were degranulated using either IgE‐anti‐TNP and OVA‐TNP (IgE/Ag) or by calcium ionophore A23187 (CI). IL‐17A was added to the cell‐free supernatant, containing the degranulate, in the presence or absence of a serine protease inhibitor (Pefabloc SC). The levels of IL‐17A in the supernatant after 1, 4, and 24 h were measured with ELISA. Data were calculated as percent residual IL‐17A compared to control. Data are expressed as means ± SEM. ***P < 0.001 in degranulated WT sample versus degranulated serglycin^−/− sample, and WT sample with inhibitor versus no inhibitor.